Agilent Technologies Microarrays Used in Groundbreaking Prenatal Research Study
News Dec 10, 2012
The three-year collaborative study, "Chromosomal microarray versus karyotyping for prenatal diagnosis," represents a significant milestone in understanding prenatal abnormalities. Agilent SurePrint CGH microarrays were used for the majority of the 4,400 cohort samples. Use of this technology enabled researchers to detect smaller aberrations compared to traditional karyotyping.
Researchers from Emory University, Baylor College of Medicine, Columbia University and Signature Genomics collaborated in this study. Their primary objective was to evaluate the accuracy, efficacy and potential advantages of using microarray analysis compared with conventional karyotyping. Their secondary objective was to evaluate analytical performance. The study was sponsored by the National Institute of Child Health and Human Development.
Agilent was the primary contributor of microarrays and reagents used in this study; 71 percent of samples were run on Agilent SurePrint CGH microarrays. Agilent assisted investigators in developing customized arrays for the study.
"We are honored to have participated in this landmark study, furthering technology adoption for improved discovery," said Robert Schueren, vice president and general manager of Agilent's Genomics Solutions Division.
A total of 5,500 arrays were used. The majority of the samples were composed of uncultured amniotic fluid and chorionic villi. All samples were also sent to a reference lab for chromosome analysis. All data was submitted to the National Center for Biotechnology Information and is available to the public free of charge.
Agilent's custom microarrays are manufactured to customer-specified designs. They are not approved or cleared by the U.S. Food and Drug Administration for use in diagnostic procedures. Customers are responsible for FDA approval/clearance prior to diagnostic use.
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018